The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.

The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.

A gallium silica glass composition is described. The glass can be used in variety of biomedical applications

A gallium silica glass composition is described. The glass can be used in variety of biomedical applications

Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.

Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.

Provided are beverage compositions comprising a urine citrate increasing component and a urine oxalate reducing component. The beverage compositions may be provided in a ready-to-drink form or may be provided in a concentrate form. Also provided are kits comprising the beverage compositions and methods for treating various conditions using the beverage compositions.

Disclosed is a new medicinal use of anionic clay, and particularly to a use of anionic clay in preparing a lead-removing medicine. The described medicinal use of the anionic clay is capable of effectively preventing and treating lead poisoning and excessive lead, has significant lead-removing effects and little side effects, and has positive clinical significance.

Disclosed is a new medicinal use of anionic clay, and particularly to a use of anionic clay in preparing a lead-removing medicine. The described medicinal use of the anionic clay is capable of effectively preventing and treating lead poisoning and excessive lead, has significant lead-removing effects and little side effects, and has positive clinical significance.

A vitreous composition according to Table (I) is described. Continuous vitreous fibers are obtained by downdrawing said molten composition, with a length ranging from millimeters to kilometers and diameters ranging from 2 μm to 3 mm. The fibers are covered with collagen and form vitreous fabrics. The fabrics form articles with a variety of medical uses.